Jump to content

Ivermectin: Yes, No or Maybe


RR2020

Recommended Posts

On 8/30/2021 at 10:05 PM, Neeranam said:

They also make billions from the sale of Covid vaccines. 

Is that true about Merck?

All the vaccines they have worked on have been abandoned or not yet brought to market.

They have some kind of agreement with J&J is that lucrative?

 

  • Like 2
Link to comment
Share on other sites

Ivermectin Sheep Drench


This page contains information on Ivermectin Sheep Drench for veterinary use.


The information provided typically includes the following:
Ivermectin Sheep Drench Indications
Warnings and cautions for Ivermectin Sheep Drench
Direction and dosage information for Ivermectin Sheep Drench

 

https://www.drugs.com/vet/ivermectin-sheep-drench.html

 

FDA Approved!

 

 

 

sheepdrench.jpg

Edited by mtls2005
  • Like 1
  • Haha 1
Link to comment
Share on other sites

2 hours ago, transam said:

 

And this:

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

 

Conclusions:

Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant 
reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled 
prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many 
examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an 
oral agent effective in all phases of COVID-19 has been identified. 

 

  • Sad 1
Link to comment
Share on other sites

2 hours ago, JetsetBkk said:

 

And this:

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

 


Conclusions:

Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant 
reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled 
prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many 
examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an 
oral agent effective in all phases of COVID-19 has been identified. 

 

Problem being that papers like this published have been discredited one way or another............

 

Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.

Different websites (such as https://ivmmeta.com/https://c19ivermectin.com/https://tratamientotemprano.org/estudios-ivermectina/, among others) have conducted meta-analyses with ivermectin studies, showing unpublished colourful forest plots which rapidly gained public acknowledgement and were disseminated via social media, without following any methodological or report guidelines. These websites do not include protocol registration with methods, search strategies, inclusion criteria, quality assessment of the included studies nor the certainty of the evidence of the pooled estimates. Prospective registration of systematic reviews with or without meta-analysis protocols is a key feature for providing transparency in the review process and ensuring protection against reporting biases, by revealing differences between the methods or outcomes reported in the published review and those planned in the registered protocol. These websites show pooled estimates suggesting significant benefits with ivermectin, which has resulted in confusion for clinicians, patients and even decision-makers. This is usually a problem when performing meta-analyses which are not based in rigorous systematic reviews, often leading to spread spurious or fallacious findings.36

 

Concluding, research related to ivermectin in COVID-19 has serious methodological limitations resulting in very low certainty of the evidence, and continues to grow.37–39 The use of ivermectin, among others repurposed drugs for prophylaxis or treatment for COVID-19, should be done based on trustable evidence, without conflicts of interest, with proven safety and efficacy in patient-consented, ethically approved, randomised clinical trials.

 

https://ebm.bmj.com/content/early/2021/05/26/bmjebm-2021-111678

 

AND with another published paper: 

Larger trials will be needed to confirm these preliminary findings. 

 

https://pubmed.ncbi.nlm.nih.gov/

 

  • Like 2
Link to comment
Share on other sites

On 9/2/2021 at 2:11 AM, cdemundo said:

Is that true about Merck?

All the vaccines they have worked on have been abandoned or not yet brought to market.

They have some kind of agreement with J&J is that lucrative?

 

Strange isn’t it?

looking through my vaccine records and it’s all Merck and Sanofil Pasteur, yet both giants of the vaccine Industry have completely drawn a blank with COVID19 

  • Like 1
  • Haha 1
Link to comment
Share on other sites

13 hours ago, FridgeMagnet1 said:

Strange isn’t it?

looking through my vaccine records and it’s all Merck and Sanofil Pasteur, yet both giants of the vaccine Industry have completely drawn a blank with COVID19 

 

Why is it "strange"? What is so strange about your vaccination records?

 

Do you often find things which are "strange"?

 

 

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

 

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.

 

 

https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/

 

 

 

I think it's strange that ivermectineers moan about "Big Pharma", while extolling sheep drench developed by Big Pharma. Go figure.

  • Like 1
  • Thanks 1
Link to comment
Share on other sites

8 hours ago, placeholder said:

There was also Curevac, a German company and a pioneer in mRNA therapy. Its vaccine failed as well. Fridgemagnet possibly was being ironic, but lots of anti-vaxxers cast suspicion on the vetting process for vaccine. They often claim that the approval is somehow corrupt. But as actual history shows, even the biggest of big pharma companies often fail.

No, I find it strange (not suspicious) that two of the biggest vaccine manufacturers in the world, with all their resources and experience, have been unable to produce an effective Covid vaccine.
As I suspect are the EU (and to a lesser extent the UK) who bet big on Sanofil in 2020

 

no suspicion or allegations of a coverup, or claims of Wumao activity or any other paranoid notions. Just that it’s odd that 2 major vaccine manufacturers have seemingly struck a blank (so far) 

  • Like 1
Link to comment
Share on other sites

16 hours ago, mtls2005 said:

 

Why is it "strange"? What is so strange about your vaccination records?

 

Do you often find things which are "strange"?

 

 

Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

 

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Merck continues to advance clinical programs and to scale-up manufacturing for two investigational medicines, MK-7110 and MK-4482 (molnupiravir); molnupiravir is being developed in collaboration with Ridgeback Bio.

 

 

https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/

 

 

 

I think it's strange that ivermectineers moan about "Big Pharma", while extolling sheep drench developed by Big Pharma. Go figure.

["Why is it "strange"? What is so strange about your vaccination records?

Do you often find things which are "strange"?]

 

Wow. Why so hostile?

That was an innocuous remark about how two industry heavy weights had not yet brought a vaccine to market.

 

 

Link to comment
Share on other sites

8 hours ago, xylophone said:

Much of what is reported in this review, and that is all it is, has been disproved and one major review in it from which much info was taken, has been withdrawn because it is inaccurate.

 

Sure it is a good treatment for parasites and worms, but even the manufacturer of the drug says it is not useful in treating Covid 19. 

Don't reply. Just report fake news websites like this.

Link to comment
Share on other sites

https://pubmed.ncbi.nlm.nih.gov/34145166/
 

Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
 

 

  • Like 1
  • Haha 1
Link to comment
Share on other sites

Guest
This topic is now closed to further replies.
  • Recently Browsing   0 members

    • No registered users viewing this page.




×
×
  • Create New...